References
1. Physicians' Desk Reference, 53rd edition (Montvale, NJ: Medical Economics Company, 1999).
2. Abbott GF, Sesti F, Splawski I, et al., MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97: 175-187 (1999) [MLUI 99235979] These data were contributed by Drs. Dan M. Roden and Tao Yang.
3. Anderson JL and Prystowsky EN, Sotalol: an important new antiarrhythmic, Am Heart J 137(3): 388-409 (1999) [MLUI 99158551].
4. Anderson ME, Mazur A, Yang T, and Roden DM, Potassium Current Antagonist Properties and Proarrhythmic Consequences of Quinolone Antibiotics. J Pharmacol Exp Ther 296(3): 806-810, 2001.
5. Anson BD, Weaver JGR, Ackerman MJ, Akinsete O, Henry K, January CT, et al., Blockade of HERG channels by HIV protease inhibitors, Lancet 365(9460): 682-686 (2005).
6. Antzelevitch C, Belardinelli L, Wu L, et al., Electrophysiologic properties and antiarrhythmic properties of a novel antianginal agent, J Cardiovasc Pharmacol Therapeut 9 (supp I): S66-S83 (2004).
7. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1791 to McTavish D and Sorkin EM, Verapamil: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension, Drugs 38: 19-76 (1989) [MLUI 89356324].
8. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1714 to Gill J, Heel RC, and Fitton A, Amiodarone: an overview of its pharmacological properties and review of its therapeutic use in cardiac arrhythmias, Drugs 43: 69-110 (1992) [MLUI 92209431].
9. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1715 to Schulz P, Dick P, Blaschke TF, and Hollister L, Discrepancies between pharmacokinetic studies of amitriptyline, Clin Pharmacokinet 10: 257-268 (1985) [MLUI 8525581].
10. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1721 to Duchin KL, McKinstry DN, Cohen AI, and Migdalof BH, Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases, Clin Pharmacokinet 14: 241-259 (1988) [MLUI 88270801].
11. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1737 to Blyden GT, Greenblatt DJ, Scavone JM, and Shader RI, Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration, J Clin Pharmacol 26: 529-533 (1986) [MLUI 87009149].
12. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1775 to Benet LZ and Ding RW, "Die renale Elimination von Procainamide: Pharmacokinetik bei Niereninsuffizienz," in Braun J, Pilgrim R, Gessler U, and Seybold D (eds), Die Behandlung von Herzrhythmusstoerungen bei Nierenkranken (Basel: S. Karger, 1984), 96-111.
13. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1776 to Colangelo PM, Blouin RA, Steinmetz JE, McNamara PJ, DeMaria AN, and Wedlund PJ, Age and propranolol stereoselective disposition in humans, Clin Pharmacol Ther 51: 489-494 (1992) [MLUI 92266651].
14. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1777 to Verme CN, Ludden TM, Clementi WA, and Harris SC, Pharmacokinetics of quinidine in male patients: A population analysis, Clin Pharmacokinet 22: 468-480 (1992) [MLUI 92266648].
15. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1777 to Atkinson AJ, Jr., Ruo TI, Piergies AA, et al., Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method, Clin Pharmacol Ther 46: 182-189 (1989) [MLUI 89337285].
16. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1777 to Zaccara G, Messori A, and Moroni F, Clinical pharmacokinetics of valproic acid 1988, Clin Pharmacokinet 15: 367-389 (1988) [MLUI 89209526].
17. Attributed by Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1777 to Dahl SG and Strandjord RS, Pharmacokinetics of chlorpromazine after single and chronic dosage, Clin Pharmacol Ther 21: 437-448 (1977).
18. Attributed by Delpón E, Valenzuela C, and Tamargo J, Blockade of cardiac potassium and other channels by antihistamines, Drug Safety 21(supplement 1): 11-18 (1999) to Delpón E, Valenzuela C, Gay P, et al., Block of human cardiac Kv1.5 channels by loratidine, Cardiovasc Res 35: 341-350 (1997) [PMUI 11181910].
19. Attributed by Delpón E, Valenzuela C, and Tamargo J, Blockade of cardiac potassium and other channels by antihistamines, Drug Safety 21(supplement 1): 11-18 (1999) to Delpón E, Valenzuela C, Gay P, et al., Block of human cardiac Kv1.5 channels by loratidine, Cardiovasc Res 35: 341-350 (1997).
20. Attributed by Delpón E, Valenzuela C, and Tamargo J, Blockade of cardiac potassium and other channels by antihistamines, Drug Safety 21(supplement 1): 11-18 (1999) to Valenzuela C, Delpón E, Franqueza L, et al., Comparative effects of nonsedating H1-receptor antagonists, ebastine and terfenadine, on human Kv1.5 channels, Eur J Pharmacol 326: 257-263 (1997).
21. Attributed by Kodama I, Kamiya K, and Toyama J, Cellular electropharmacology of amiodarone, Cardiovasc Res 35: 13-29 (1997) to Kamiya K, Cheng J, Kodama I, Toyama J, "Acute and chronic effects of amiodarone on action potential and ionic currents in single rabbit ventricular myocytes" in Toyama J, Hiraoka M, and Kodama I (eds), Recent Progress in Electropharmacology of the Heart (Boca Raton, FL: CRC Press, 1995): 139-149.
22. Attributed by Kodama I, Kamiya K, and Toyama J, Cellular electropharmacology of amiodarone, Cardiovasc Res 35: 13-29 (1997) to Guo W, Kamiya K, and Toyama J, Evidences of antagonism between amiodarone and triiodothyronine on the K+ channel activities of cultured rat cardiomyocytes, J Mol Cell Cardiol 29: 617-627 (1997) [MLUI 97285603].
23. Attributed by Kodama I, Kamiya K, and Toyama J, Cellular electropharmacology of amiodarone, Cardiovasc Res 35: 13-29 (1997) to Mori K, Saito T, Masuda Y, and Nakaya H, Effects of class III antiarrhythmic drugs on the Na+-activated K+ channels in guinea-pig ventricular cells, Br J Pharmacol 119: 133-141 (1996).
24. Attributed by Kodama I, Kamiya K, and Toyama J, Cellular electropharmacology of amiodarone, Cardiovasc Res 35: 13-29 (1997) to Watanabe Y, Hara Y, Tamagawa M, Nakaya H, Inhibitory effect of amiodarone on the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells, J Pharmacol Exp Ther 279: 617-624 (1996).
25. Attributed by Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, and January CT, Torsade de pointes with an antihistamine metabolite: Potassium-channel blockade with desmethylastemizole, J Am Coll Cardiol 28(5): 1556-1561 (1996) to Heykants J, Van Peer A, Woestenborghs R, Jageneau A, and Vanden Bussche G, Dose-proportionality, bioavailability, and steady-state kinetics of astemizole in man, Drug Develop Res 8: 71-78 (1986).
26. Bellocq C, Wilders R, Schott J-J, Louérat-Oriou B, Boisseau P, Le Marec H, Escande D, A common antitussive drug, clobutinol, precipitates in LQT2 syndrome, Circulation 110(17): III-17 (2004)
27. Benavides J, Schoemaker H, Dana C, et al., In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent, Drug Res 45(I, 5): 551-558 (1995).
28. Berger F, Borchard U, and Hafner D, Effects of the calcium-entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibers, Naunyn Schmiedebergs Arch Pharmacol 339(6): 638-646 (1989) [MLUI 89365224].
29. Bertran GC, Biagetti MO, Valverde ER, and Quintiero RA, Effects of amiodarone and desethylamiodarone on the inward rectifying potassium current (IKr) in rabbit ventricular myocytes, J Cardiovasc Pharmacol 31: 914-920 (1998) [MLUI 98303179].
30. Berul C and Morad M, Regulating of potassium channels by non-sedating antihistamines, Circulation 91:2220-2225 (1995).
31. Berul CI and Morad M, Regulation of potassium channels by nonsedating antihistamines, Circulation 91(8): 2220-2225 (1995). See also Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF, Guinosso PJ, and Lynch JJ, Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine, Circ Res 76(1): 110-119 (1995). [MLUI 95211978].
32. Bhattacharyya ML, Sarker S, Mull KP, and Debnam Q, Clofilium-induced block of delayed rectifier type K+ current in atrial tumor cells (AT-1 cells), J Mol Cell Cardiol 29: 301-307 (1997) [MLUI 97192226]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
33. Bischoff U, Schmidt C, Netzer R, and Pongs O, Effects of fluoroquinolones on HERG currents, Eur J Pharmacol, 406 (3): 341-343 (2000) [PMUI 11040340]. This reference was brought to my attention by Icilio Cavero.
34. Busch AE, Eigenberger B, Jurkiewicz NK, et al., Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action, Br J Pharmacol 123: 23-30 (1998) [MLUI 98143381]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
35. Caballero R, Moreno I, Gonzalez T, Arias C, Valenzuela C, Delpon E, and Tamargo, J, Spironolactone and its main metabolite, canrenoic acid, block human ether-a-go-go-related gene channels, Circulation 107(6):889-895 (2003).
36. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, and Wadstedt G, Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: Implications for proarrhythmic potential, J Pharmacol Exp Ther 282(1): 220-227 (1997) [MLUI 97366727].
37. Carmeliet E, Effects of cetirizine on the delayed K+ currents in cardiac cells: comparison with terfenadine, Br J Pharmacol 124: 663-668 (1998) [MLUI 98353167].
38. Carmeliet E, Use-dependent block and use-dependent unblock of the delayed-rectifier K+ current by almokalant in rabbit ventricular myocytes, Circ Res 73: 857-868 (1993) [MLUI 94006985]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
39. Carmeliet E, Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide, J Pharmacol Exp Ther 262(2): 809-817 (1992) [MLUI 92364899].
40. Chachin M, Katayama Y, Yamada M, et al., Eur J Pharmacol 374: 457-460 (1999) [MLUI 99349652]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
41. Chen Y and Woosley RL, Ketoconazole blocks potassium currents in feline heart, Circulation 88(4 part 2): I-38 (1993).
42. Chouabe C, Drici M-D, Romey G, Barhanin J, and Lazdunski M, HERG and KvLQT1/IsK, the cardiac K+ channels involved in long-QT syndromes, are targets for calcium-channel blockers, Mol Pharmacol 54: 695-703 (1998) [MLUI 98440643].
43. Claycomb WC, Lanson NA Jr, Stallworth BS, et al., HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte, Proc Natl Acad Sci 95: 2979-2984 (1998) [MLUI 98169482]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
44. Cohen ML, Carpenter R, Schenck K, Wittenauer L, and Mason N, Effect of nitrendipine, diltiazem, trifluoperazine, and pimozine on serotinin-2 (5-HT2) receptor in the rat uterus and jugular vein, J Pharmacol Exp Ther 238 (3): 860-867 (1986) [MLUI 86307533].
45. Crumb WJ Jr, Loratidine blockade of K+ channels in human heart: comparison with terfenadine under physiological conditions, J Pharmacol Exp Ther 292 (1): 261-264 (2000).
46. Crumb WJ Jr, personal communication, 9 August 2000.
47. Daleau P, Lessard E, Groleau M-F, and Turgeon J, Erythromycin blocks the rapid component of the delayed-rectifier potassium current and lengthens repolarization of guinea-pig ventricular myocytes, Circulation 91(12): 3010-3016 [MLUI 95316971].
48. Drolet B, Khalifa M, Daleau P, Hamelin BA, and Turgeon J, Block of the rapid component of the delayed-rectifier potassium current by the prokinetic agent cisapride underlies drug-related lengthening of the QT interval, Circulation 97: 204-210 (1998) [MLUI 98105952].
49. Drolet B, Vincent F, Rail J, et al, Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed-rectifier potassium current, J Pharmacol Exp Ther 288(3): 1261-1268 (1999) [MLUI 99152188].
50. Ducic I, Ko CM, Shuba YM, and Morad M, Comparative effects of loratidine and terfenadine on cardiac K+ channels, J Cardiovasc Pharmacol 30(1): 42-54 (1997) [MLUI 97412107].
51. Dumaine R, Roy M-L, and Brown AM, Blockade of HERG and Kv1.5 by ketoconazole, J Pharmacol Exp Ther 286(2): 727-735 (1998) [MLUI 98362048].
52. Fang LM and Osterrieder W, Potential-dependent inhibition of cardiac Ca2+ inward currents by Ro 40-5967 and verapamil: relation to negative inotropy, Eur J Pharmacol 196(2):205-207 (1991) [MLUI 91339943].
53. Feng J, Wang Z, Li GR, and Nattel S, Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes, J Pharmacol Exp Ther 281(1): 384-392 (1997).
54. Fermini B, Jurkiewicz NK, Jow B, et al., Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed-rectifier potassium and L-type calcium currents, J Cardiovasc Pharmacol 26(2): 259-271 (1995) [MLUI 96078508].
55. Follmer CH, Cullinan CA, and Colatsky TJ, Differential block of cardiac delayed-rectifier current by class Ic antiarrhythmic drugs: evidence for open-channel block and unblock, Cardiovasc Res 26: 1121-1130 (1992) [MLUI 93177790]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
56. Geelen P, Drolet B, Rail J, O'Hara GE, and Turgeon J, Sildenafil (Viagra) may lengthen cardiac repolarization by blocking the rapid component of the delayed-rectifier potassium current, Circulation 100 (18): I-280 (1999).
57. Hara Y and Nakaya H, SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholine-receptor-operated potassium current in guinea-pig atrial cells, Br J Pharmacol 116(6): 2750-2756 (1995) [MLUI 96160976].
58. Heath BM and Terrar DA, Effect of glibenclamide, forskolin, and isoprenaline on the parallel activation of KATP and reduction of IK by cromakalim in cardiac myocytes, Cardiovasc Res 28 (6): 818-822 (1994) [MLUI 95007681] .
59. Horie M and Yoshida H, An antiarrhythmic agent with class Ib action, aprinidine, inhibits human IKr but not IKs heterologously expressed in COS7 cells, Circulation 100(18): I-280 (1999).
60. Jones SE, Ogura T, Shuba L, and McDonald TF, Inhibition of the rapid component of the delayed-rectifier K+ current by therapeutic concentration of the antispasmodic agent terodiline, Br J Pharmacol 125: 1138-1143 (1998) [MLUI 99079343]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
61. Jurkiewicz NK, Sanguinetti MC, Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide Class III antiarrhythmic agent, Circ Res 72(1): 75-83 (1993) [MLUI 93113855].
62. Jurkiewicz NK, Wang J, Fermini B, Sanguinetti MC, and Salata JJ, Mechanism of action-potential prolongation by RP 58866 and its active enantiomer, terikalant: Block of the rapidly-activating delayed-rectifier K+ current, IKr, Circulation 94: 2938-2946 (1996) [MLUI 97096100]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
63. Kamei C, Mio M, Izushi K, et al., Antiallergic effects of major metabolites of astemizole in rats and guinea pigs, Arzneim.-Forsch/Drug Res 41(II): 932-936 (1991) [MLUI 92181488].
64. Kamiya K, Nishiyama A, Yasui K, Hojo M, Sanguinetti MC, and Kodama I, Short- and log-term effects of amiodarone on the two components of cardiac delayed rectifier K+ current, Circulation 103 (9):1317-1324 (2001).
65. Kang J, Wang L, Cai F, and Rampe D, High-affinity blockade of the HERG K+ channel by the neuroleptic pimozide, Eur J Pharmacol 392: 137-140 (2000).
66. Kang J, Wang L, Chen XL, Triggle DJ, and Rampe D, Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG, Mol Pharmacol, 59(1): 122-126, 2001 [PMUI 11125032]. This reference was brought to my attention by Icilio Cavero.
67. Kapusnik-Uner JE, Sande MA, and Chambers HF, Tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents in Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1137.
68. Kapusnik-Uner JE, Sande MA, and Chambers HF, Tetracyclines, chloramphenicol, erythromycin, and miscellaneous antibacterial agents in Hardman JG and Limbird LE (eds), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edition (New York: McGraw-Hill, 1996), 1135.
69. Karle CA, Schoels, Thomas D, and Kiehn T, The beta-blocker carvedilol inhibits the HERG potassium channel in its closed state, Circulation 100 (18): I-279 (1999)
70. Katchman AN, McGroary KA, Kilborn MJ, et al., Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents, J Pharmacol Exp Ther 303 (2): 688-694 (2002).
71. Katchman AN, McGroary KA, Kilborn MJ, et al., Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents, J Pharmacol Exp Ther 303(2): 688-94 (2002). This reference was brought to my attention by Mark Haigney.
72. Khalifa M, Drolet B, Daleau P, et al., Block of potassium currents in guinea-pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1-receptor antagonist diphenhydramine, J Pharmacol Exp Ther 288: 858-865 (1999) [MLUI 99349652]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
73. Kiehn J, Thomas D, Karle CA, Schols W, and Kubler W, Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels, Naunyn Schmiedebergs Arch Pharmacol 359: 212-219 (1999) [MLUI 99222989]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
74. Kii Y, Inui A, and Ito T, Effects of histamine H1-receptor antagonists on action potentials in guinea-pig isolated papillary muscles, Arch Int Pharmacodyn 331: 59-73 (1996) [MLUI 97052076].
75. Ko CM, Ducic I, Fan J, Shuba YM, and Morad M, Suppression of mammalian K+ channel family by ebastine, J Pharmacol Exper Ther 281(1): 233-244 (1997) [MLUI 97256661].
76. Lacerda AE, Kramer J, Shen, K-Z, Thomas D, and Brown AM, Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs, Eur Heart J Supplements 3 (suppl K): K23-K30 (2001).
77. Lacerda AE, Roy ML, Lewis EW, and Rampe D, Interactions of the nonsedating antihistamine loratidine with a Kv1.5-type potassium channel cloned from human heart, Mol Pharmacol 52(2): 314-322 (1997).
78. Le Grand B, Marty A, Colpaert FC, and John GW, Ketanserin inhibits the transient outward current in rabbit ventricular myocytes, J Cardiovasc Pharmacol 25(2): 341-344 (1995) [MLUI 95272113].
79. Le Grand B, Talmant J-M, Rieu J-P, Patoiseau J-F, Colpaert FC, and John GW, Investigation of the mechanism by which ketanserin prolongs the duration of the cardiac action potential, J Cardiovasc Pharmacol 26(5): 803-809 (1995) [MLUI 96194009]. Also attributed by Dan Roden to Zhang et al, 1994.
80. Lees-Miller JP, Duan Y, and Duff HJ, Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites, Circulation 100(18): I-424 (1999).
81. Lees-Miller JP, Kondo C, Wang L, and Duff HJ, Electrophysiological characterization of an alternatively processed ERG K+ channel in mouse and human hearts, Circ Res 81: 719-726 (1997) [MLUI 98012799]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
82. Liu S, Melchert RB, Kennedy RH, Inhibition of L-type Ca++ channel current in rat ventricular myocytes by terfenadine, Circ Res 81(2): 202-210 (1997) [MLUI 97386187].
83. Liu S, Rasmusson RL, Campbell DL, Eanf S, and Strauss HC, Activation and inactivation kinetics of an E-4031-sensitive current from single ferret atrial myocytes, Biophys J 70: 2704-2715 (1996) [MLUI 96363748]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
84. Liu XK, Katchmann A, Ebert SN, and Woosley RL, The antiestrogen tamoxifen blocks the delayed-rectifier potassium current, IKr, in rabbit ventricular myocytes, J Pharmacol Exp Ther 287: 877-883 (1998) [MLUI 99081794]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
85. Loussouarn G, Charpentier F, Mohammad-Panah R, Kunzelmann K, Baró I, and Escande D, KvLQT1 potassium channel but not IsK is the molecular target for trans-6-cyano-4-(N-ethylsulfonyl-N-methylamino)-3-hydroxy-2,2-dimethyl-chromane, Mol Pharmacol 52: 1131-1136 (1997).
86. Markham A and Wagstaff AJ, Fexofenadine, Drugs 55(2):269-274 (1998) [MLUI 9506246].
87. Masuoka H, Ito M, Sugioka M, et al., Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent, Biochem Biophys Res Comm 190(2): 412-417 (1993).
88. Mehrke G, Zong XG, Flockerzi V, and Hofmann F, The Ca++-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++ channels, J Pharmacol Exp Ther 271(3): 1483-1488 (1994) [MLUI 95088934].
89. Mine Y, Yoshikawa T, Oku S, Nagai R, Yoshida N, and Hoski K, Comparison of effect of mosapride citrate and existing 5-HT4-receptor agonists on gastrointestinal motility in vivo and in vitro, J Pharmacol Exp Ther 283(3): 1000-1008 (1997).
90. Ming Z and Nordin C, Terfenadine blocks time-dependent Ca++, Na+, and K+ channels in guinea-pig ventricular myocytes, J Cardiovasc Pharmacol 26:761-769 (1995) [MLUI 96194004].
91. Mohammad S, Zhou Z, Gong Q, and January CT, Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride, Am J Physiol 273: H2534-H2538 (1997) [MLUI 98042207].
92. Momtaz A, Robineau P, and Caille D, Alfuzosin (SL77.0499-10): effects on the HERG channel stably expressed in mammalian cell line -- comparison with tamsulosin, doxazosin, prazosin, and terazosin. Sanofi Report 00-00329-EN-00 dated 1/10/01.
93. Nishimura M, Follmer CH, and Singer DH, Amiodarone blocks calcium current in single guinea-pig ventricular myocytes, J Pharmacol Exp Ther 251(2): 650-659 (1989) [MLUI 90040226].
94. Rampe D, Murawsky MK, Grau J, and Lewis EW, The antipsychotic agent sertindole is a high-affinity antagonist of the human cardiac potassium channel HERG, J Pharmacol Exp Ther 286(2): 788-793 (1998) [MLUI 98362056].
95. Rampe D, Roy M-L, Dennis A, and Brown AM, A mechanism for the proarrhythmic effects of cisapride (Propulsid): high-affinity blockade of the human cardiac potassium channel HERG, FEBS Letters 417: 28-32 (1997) [MLUI 98055446].
96. Rampe D, Voltage-dependent potassium channels cloned from human heart: New tools to predict the pro-arrhythmic potential of drugs, ID research alert 2(9): 331-337 (1997). See also Roy M-L, Dumaine R, and Brown AM, HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine, Circulation 94(4): 817-823 (1996) and Taglialatela M, Pannaccione A, Castaldo P, et al., Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor-blocker cetirizine compared with other second-generation antihistamines, Mol Pharmacol 54: 113-121 (1998).
97. Roden DM, personal communication (11 April 2000).
98. Rodin DM, personal communication (3 March 2000).
99. Rosati B, Rocchetti M, Zaza A, and Wanke E, Sulfonylureas blockade of neural and cardiac HERG channels, FEBS Letters 440: 125-130 (1998).
100. Roy M-L, Dumaine R, and Brown AM, HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine, Circulation 94(4): 817-823 (1996) [MLUI 96368698].
101. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF, Guinosso PJ, and Lynch JJ, Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine, Circ Res 76(1): 110-119 (1995) [MLUI 95094412].
102. Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF, Guinosso PJ, and Lynch JJ, Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine, Circ Res 76(1): 110-119 (1995)
103. Sanguinetti MC and Jurkiewicz NK, Two components of cardiac delayed-rectifier K+ current: Differential sensitivity to block by class III antiarrhythmic agents, J Gen Physiol 96: 195-215 (1990) [MLUI 91011319]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
104. Schotte A, Janssen PF, Gommeren W, et al., Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding, Psychopharmacology (Berl) 124: 57-73 (1996).
105. Snyders DJ and Chaudhary A, High-affinity open-channel block by dofetilide of HERG expressed in a human cell line, Mol Pharmacol 49: 949-955 (1996) [MLUI 96251689]. These data were contributed by Drs. Dan M. Roden and Tao Yang
106. Spector PS, Curran ME, Keating MT, and Sanguinetti MC, Class III antiarrhythmic drugs block HERG, a human cardiac delayed-rectifier K+ current: Open-channel block by methanesulfanilides, Circ Res 78: 499-503 (1996) [MLUI 96172930]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
107. Spinelli W, Moubarak IF, Parsons RW, and Colatsky T, Cellular electrophysiology of WAY-123,398, a new class III antiarrhythmic agent: specificity of IK block and lack of reverse use-dependence in cat ventricular myocytes, Cardiovasc Res 27: 1580-1591 (1993) [MLUI 94116018]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
108. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, and Busch AESO, The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes, Br J Pharmacol 120(5): 968-974 (1997) [MLUI 97227128].
109. Suessbrich H, Schonherr R, Heinemann SH, Lang F, and Busch AE, Specific block of cloned HERG channels by clofilium and its tertiary analog LY97241, FEBS Letters 414: 435-438 (1997) [MLUI 97459775]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
110. Suessbrich H, Waldegger S, Lang F, and Busch AE, Blockade of HERG channels expressed in Xenopus ooctes by the histamine-receptor antagonists terfenadine and astemizole, FEBS Letters 385: 77-80 (1996) [MLUI 96200173].
111. Taglialatela M, Pannaccione A, Castaldo P, et al., Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor-blocker cetirizine compared with other second-generation antihistamines, Mol Pharmacol 54: 113-121 (1998) [MLUI 98325250].
112. Teschemacher AG, Seward EP, Hancox JC, and Witchel HJ, Inhibition of the current of heterologously-expressed HERG potassium channels by imipramine and amitriptyline, Br J Pharmacol 128: 479-485 (1999) [MLUI 99441297].
113. Thomas GP, Karmazyn M, Zygmunt AC, Antzelevitch C, and Narayanan N, The antifungal antibiotic clotrimazole potently inhibits L-type calcium current in guinea-pig ventricular myocytes, Br J Pharmacol 126(7): 1531-1533 (1999) [PMUI 0010323582].
114. Tie H, Walker BD, Valenzuela SM, Breit SN, and Campbell TJ, The heart of psychotropic drug therapy, Lancet 355 (9217): 1825 (2000).
115. Toyama J, Kamiya K, Cheng J, Lee J-K, Suzuki R, and Kodama I, Vesnarinone prolongs action-potential duration without reverse frequency-dependence in rabbit ventricular muscle by blocking the delayed-rectifier K+ current, Circulation 96: 3696-3703 (1997) [MLUI 98057159].
116. Trudeau MC, Warmke JW, Ganetzky B, and Robertson GA, HERG, a human inward rectifier in the voltage-gated potassium channel family, Science 269: 92-95 (1995) [MLUI 95327958]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
117. Turgeon J, Daleau P, Bennett PB, Wiggins SS, Selby L, and Roden DM, Block of IKs, the slow component of the delayed-rectifier K+ current, by the diuretic agent indapamide in guinea-pig myocytes, Circ Res 75(5): 879-886 (1994) [MLUI 95008072].
118. Turko IV, Ballard SA, Francis SH, and Corbin JD, Inhibition of cyclic-GMP-binding cyclic-GMP-specific phosphodiesterase (type 5) by sildenafil and related compounds, Mol Pharmacol 56 (1): 124-130 (1999) [MLUI 99253914].
119. Valenzuela C, Delpon E, Franqueza L, Gay P, Vicente J, and Tamargo J, Comparative effects of nonsedating histamine H1-receptor antagonists ebastine and terfenadine on human Kv1.5 channels, Eur J Pharmacol 326(2-3): 257-263 (1997).
120. Virag L, Varro A, and Papp JG, Effect of disopyramide on potassium currents in rabbit ventricular myocytes, Naunyn Schmiedebergs Arch Pharmacol 357(3): 268-275 (1998) [MLUI 98209668].
121. Vorperian VR, Zhou Z, Mohammad S, Hoon TJ, Studenik C, and January CT, Torsade de pointes with an antihistamine metabolite: Potassium-channel blockade with desmethylastemizole, J Am Coll Cardiol 28(5): 1556-1561 (1996).
122. Waldegger S, Niemeyer G, Morike K, et al., Effect of verapamil enantiomers and metabolites on cardiac K+ channels expressed in Xenopus oocytes, Cell Physiol Biochem 9: 81-89 (1999) [PMUI 10394001]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
123. Walker BD, Singleton CB, Bursill JA, et al., Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states, Br J Pharmacol 128: 444-450 (1999) [MLUI 99441292].
124. Walker BD, Valenzuela SM, Singleton CB, et al., Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate, Br J Pharmacol 127: 243-251 (1999) [MLUI 99296170]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
125. Wooltorton JRA and Mathie A, Block of potassium currents in rat isolated sympathetic neurones by tricyclic antidepressants and structurally related compounds, Br J Pharmacol 110(3): 1126-1132 (1993) [MLUI 94129903].
126. Woosley RL, Chen Y, Freiman JP, and Gillis RA, Mechanism of the cardiotoxic actions of terfenadine, JAMA 269(12): 1532-1536 (1993) [MLUI 93188285].
127. Yang T and Roden DM, The effects of erythromycin and several antibiotics on IKr in AT-1 cells (personal communication, 1999).
128. Yang T, Prakash C, Roden DM, and Snyders DJ, Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers, Br J Pharmacol 115(2): 267-274 (1995).
129. Yang T, Snyders DJ, and Roden DM, Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: comparison with quinidine and dofetilide, J Pharmacol Exp Ther 280: 1170-1175 (1997) [MLUI 97219925]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
130. Yang T, Snyders DJ, and Roden DM, Discordance between IKr block and torsade de pointes, Circulation 96: I-554 (1997).
131. Yang T, Snyders DJ, and Roden DM, Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly-activating delayed-rectifier K+ current (IKr) in AT-1 cells, Circulation 91(6): 1799-1806 (1995) [MLUI 95188337].
132. Yatani A and Akaike N, Blockage of the sodium current in isolated single cells from rat ventricle with mexiletine and disopyramide, J Mol Cell Cardiol 17(5): 467-476 (1985) [MLUI 85293108].
133. Yatani A and Brown AM, The calcium-channel blocker nitrendipine blocks sodium channels in neonatal rat cardiac myocytes, Circ Res 56(6): 868-875 (1985) [MLUI 85228621].
134. Yatani A, Brown AM, and Schwartz A, Bepridil block of cardiac calcium and sodium channels, J Pharmacol Exp Ther 237(1): 9-17 (1986) [MLUI 86171365].
135. Zhang S, Zhou Z, Chen Y, Gong Q, Ruoho AE, and January CT, Cocaine blocks HERG potassium channels, Circulation 100(18): I-424 (1999).
136. Zhang S, Zhou ZF, Gong QM, Makielski C, and January CT, Mechanism of block and identification of the verapamil binding domain to HERG potassium channels, Circ Res 84: 989-998 (1999) [MLUI 99263415]. Some of these data were contributed by Drs. Dan M. Roden and Tao Yang.
137. Zhou Z, Gong Q, Ye B, et al., Properties of HERG channels stably expressed in HEK-293 cells studied at physiologic temperature, Biophysic J 74: 230-241 (1998) [MLUI 98109379]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
138. Zhou Z, Vorperian VR, Gong Q, Zhang S, and January CT, Block of HERG potassium channels by the antihistamine astemizole and its metabolites desmethylastemizole and norastemizole, J Cardiovasc Electrophysiol 10: 836-843 (1999) [MLUI 99303414]. These data were contributed by Drs. Dan M. Roden and Tao Yang.
139. Zitron E, Scholz E, Owen RW, et al., QTc prolongation by grapefruit juice and its potential pharmacological basis: HERG channel blockade by flavonoids, Circulation 111(7): 835-838 (2005).
140. Zygmunt AC, Thomas GP, Belardinelli L, Blackburn B, and Antzelevitch C, Ranolazine produces ion-channel effects similar to those observed with chronic amiodarone in canine cardiac ventricular myocytes, NASPE Abstract #100793, 2002.
HTML generated 12/25/2010 1:35:12 PM by g:\source code\delphi\applications\webqt\newwebqt.exe